Therapeutic strategies of targeting non-apoptotic regulated cell death (RCD) with small-molecule compounds in cancer

• Published in: Acta pharmaceutica Sinica. B Vol. 14; no. 7; pp. 2815 - 2853
• Main Authors: Jin, Xin, Jin, Wenke, Tong, Linlin, Zhao, Jia, Zhang, Lan, Lin, Na
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-07-2024; Elsevier
• Subjects: Autophagy; Cancer therapy; Ferroptosis; Necroptosis; Non-apoptotic RCD subroutine; Regulated cell death (RCD); Regulatory mechanism; Review; Small-molecule compound; Regulated cell death (RCD); Necroptosis; Regulatory mechanism; Cancer therapy; Ferroptosis; Non-apoptotic RCD subroutine; Autophagy; Small-molecule compound
• ISSN: 2211-3835; 2211-3843
• DOI: 10.1016/j.apsb.2024.04.020

Regulated cell death (RCD) is a controlled form of cell death orchestrated by one or more cascading signaling pathways, making it amenable to pharmacological intervention. RCD subroutines can be categorized as apoptotic or non-apoptotic and play essential roles in maintaining homeostasis, facilitating development, and modulating immunity. Accumulating evidence has recently revealed that RCD evasion is frequently the primary cause of tumor survival. Several non-apoptotic RCD subroutines have garnered attention as promising cancer therapies due to their ability to induce tumor regression and prevent relapse, comparable to apoptosis. Moreover, they offer potential solutions for overcoming the acquired resistance of tumors toward apoptotic drugs. With an increasing understanding of the underlying mechanisms governing these non-apoptotic RCD subroutines, a growing number of small-molecule compounds targeting single or multiple pathways have been discovered, providing novel strategies for current cancer therapy. In this review, we comprehensively summarized the current regulatory mechanisms of the emerging non-apoptotic RCD subroutines, mainly including autophagy-dependent cell death, ferroptosis, cuproptosis, disulfidptosis, necroptosis, pyroptosis, alkaliptosis, oxeiptosis, parthanatos, mitochondrial permeability transition (MPT)-driven necrosis, entotic cell death, NETotic cell death, lysosome-dependent cell death, and immunogenic cell death (ICD). Furthermore, we focused on discussing the pharmacological regulatory mechanisms of related small-molecule compounds. In brief, these insightful findings may provide valuable guidance for investigating individual or collaborative targeting approaches towards different RCD subroutines, ultimately driving the discovery of novel small-molecule compounds that target RCD and significantly enhance future cancer therapeutics.
Non-apoptotic RCD subroutines have been extensively studied in cancer, and related small-molecule compounds are continuously being developed to improve cancer therapy. [Display omitted]